SG11201906682YA - Glucagon receptor binding proteins and methods of use thereof - Google Patents
Glucagon receptor binding proteins and methods of use thereofInfo
- Publication number
- SG11201906682YA SG11201906682YA SG11201906682YA SG11201906682YA SG11201906682YA SG 11201906682Y A SG11201906682Y A SG 11201906682YA SG 11201906682Y A SG11201906682Y A SG 11201906682YA SG 11201906682Y A SG11201906682Y A SG 11201906682YA SG 11201906682Y A SG11201906682Y A SG 11201906682YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- south san
- san francisco
- pct
- binding proteins
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 108091009748 glucagon receptor binding proteins Proteins 0.000 title abstract 2
- 235000020636 oyster Nutrition 0.000 abstract 5
- 241000237502 Ostreidae Species 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 1
- 102100040890 Glucagon receptor Human genes 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 229960000074 biopharmaceutical Drugs 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a 600 • -•500 .-! DOX 0 1 2 3 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 August 2018 (02.08.2018) WIP0 I PCT Hu onus °nolo olomonliomioluo ow (10) International Publication Number WO 2018/140729 Al (51) International Patent Classification: A61K 39/00 (2006.01) C07K 16/00 (2006.01) A61K 39/395 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2018/015452 (22) International Filing Date: 26 January 2018 (26.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/451,603 27 January 2017 (27.01.2017) US (71) Applicant: NGM BIOPHARMACEUTICALS, INC. [US/US]; 333 Oyster Point Blvd, South San Francisco, CA 94080 (US). (72) Inventors: SHEN, Wenyan; 333 Oyster Point Blvd, South San Francisco, CA 94080 (US). WANG, Yan; 333 Oys- ter Point Blvd, South San Francisco, CA 94080 (US). MATERN, Hugo; 333 Oyster Point Blvd, South San Fran- cisco, CA 94080 (US). LIU, Zhonghao; 333 Oyster Point Blvd, South San Francisco, CA 94080 (US). (74) Agent: WEISSER, Tamera, M. et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). — (54) Title: GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE THEREOF Fed Blood Glucose N O Weeks Post mAb Dosing FIG. 3 anti-KLH --or-3H5 3 6B5 -x .5B11 1-1 N (57) : The present disclosure provides binding proteins, such as antibodies, that bind glucagon receptors, including a human glucagon receptor, and methods of their use. [Continued on next page] C WO 2018/140729 Al MIDEDIMOMMIDIREEMOMOEMOIRMIHOMODEVOIMIE Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762451603P | 2017-01-27 | 2017-01-27 | |
| PCT/US2018/015452 WO2018140729A1 (en) | 2017-01-27 | 2018-01-26 | Glucagon receptor binding proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906682YA true SG11201906682YA (en) | 2019-08-27 |
Family
ID=62979257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906682YA SG11201906682YA (en) | 2017-01-27 | 2018-01-26 | Glucagon receptor binding proteins and methods of use thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10995145B2 (en) |
| EP (1) | EP3573651A4 (en) |
| JP (1) | JP7005638B2 (en) |
| KR (1) | KR102627311B1 (en) |
| CN (1) | CN110520151B (en) |
| AU (1) | AU2018213374B2 (en) |
| BR (1) | BR112019015479A2 (en) |
| CA (1) | CA3048913A1 (en) |
| CL (1) | CL2019002081A1 (en) |
| CO (1) | CO2019009035A2 (en) |
| IL (1) | IL267638B2 (en) |
| MX (1) | MX2019008722A (en) |
| MY (1) | MY201301A (en) |
| PE (1) | PE20191404A1 (en) |
| PH (1) | PH12019501605A1 (en) |
| SG (1) | SG11201906682YA (en) |
| UA (1) | UA129078C2 (en) |
| WO (1) | WO2018140729A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7005638B2 (en) | 2017-01-27 | 2022-02-04 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | Glucagon receptor-binding protein and how to use it |
| EP3829636A1 (en) | 2018-07-27 | 2021-06-09 | NGM Biopharmaceuticals, Inc. | Use of glucagon receptor antagonists with immunotherapeutic agent |
| MX2021007444A (en) * | 2018-12-21 | 2021-08-05 | Jiangsu Hengrui Medicine Co | Bispecific protein. |
| AU2021206449A1 (en) * | 2020-01-10 | 2022-07-21 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
| WO2022083720A1 (en) * | 2020-10-23 | 2022-04-28 | 江苏恒瑞医药股份有限公司 | Glp1-gcgr antibody fusion protein variant and composition comprising same |
| KR20230004135A (en) * | 2021-06-30 | 2023-01-06 | 한미약품 주식회사 | Therapeutic use of a combination comprising a trigonal glucagon/GLP-1/GIP receptor agonist |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK580789D0 (en) | 1989-11-20 | 1989-11-20 | Novo Nordisk As | PROCEDURE FOR PURIFICATION OF POLYPEPTIDES |
| RU2184779C2 (en) | 1992-08-28 | 2002-07-10 | Ново Нордиск А/С | Isolated dna molecule encoding glucagon receptor, dna-construction, cell line, method of preparing glucagon receptor, isolated glucagon receptor peptide, isolated antibody, probe, method of detection of glucagon antagonist presence |
| US5776725A (en) | 1992-08-28 | 1998-07-07 | Zymogenetics, Inc. | Recombinant production of glucagon receptors |
| US20040037826A1 (en) | 2002-06-14 | 2004-02-26 | Michelsen Birgitte Koch | Combined use of a modulator of CD3 and a GLP-1 compound |
| WO2006005469A2 (en) | 2004-07-15 | 2006-01-19 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr) |
| CL2007002668A1 (en) | 2006-09-20 | 2008-05-09 | Amgen Inc | ANTIGEN UNION PROTEIN THAT JOINS THE HUMAN GLUCAGON RECEIVER; NUCLEIC ACID THAT CODIFIES IT; METHOD OF PRODUCTION; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; AND ITS USE TO TREAT OR PREVENT TYPE 2 DIABETES. |
| US20110245473A1 (en) | 2007-09-26 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-IL-6 Receptor Antibody |
| RU2526517C2 (en) | 2007-10-25 | 2014-08-20 | Треллис Байосайенс,Инк. | Respiratory syncytial virus (rsv) anti-g protein antibodies |
| PE20091674A1 (en) * | 2008-03-27 | 2009-11-04 | Lilly Co Eli | GLUCAGON RECEPTOR ANTAGONISTS |
| CN103408663B (en) | 2008-10-31 | 2016-01-27 | 东丽株式会社 | Anti-human CXCL1 monoclonal antibody or its fragment |
| US9102732B2 (en) | 2009-09-08 | 2015-08-11 | Neopharm Co., Ltd. | Antibodies against glucagon receptor and their use |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
| JO3756B1 (en) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | Human antibodies to the glucagon receptor |
| WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
| US9934913B2 (en) | 2011-10-26 | 2018-04-03 | Nokia Technologies Oy | Apparatus and associated methods |
| US20140275368A1 (en) | 2013-03-14 | 2014-09-18 | Sabic Innovative Plastics Ip B.V. | Blended polymer compositions with improved mold release properties |
| RU2015147721A (en) | 2013-05-07 | 2017-06-15 | Ринат Нейросаенз Корпорэйшн | ANTIBODIES AGAINST GLUCAGON RECEPTOR AND METHODS OF USING THEM |
| CN104231083A (en) * | 2013-06-09 | 2014-12-24 | 杭州鸿运华宁生物医药工程有限公司 | Antibody for resisting to glucagon receptor and use thereof |
| WO2015154795A1 (en) | 2014-04-08 | 2015-10-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Combination therapy for the treatment of autoimmune diseases |
| WO2015189698A2 (en) | 2014-06-08 | 2015-12-17 | Beijing Cosci-Remd Bio Med Tech Company Ltd | Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies |
| CN107001461A (en) | 2014-09-16 | 2017-08-01 | 瑞泽恩制药公司 | Anti- hyperglycemic factor antibody and its application method |
| US10752693B2 (en) | 2015-04-02 | 2020-08-25 | Remd Biotherapeutics, Inc. | Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies |
| US10765737B2 (en) | 2015-09-04 | 2020-09-08 | REMD Biotherapeutics, Inc | Methods for treating heart failure using glucagon receptor antagonistic antibodies |
| WO2017062693A1 (en) | 2015-10-07 | 2017-04-13 | Remd Biotherapeutics, Inc. | Methods for treating rare genetic disorders using glucagon receptor antagonistic antibodies |
| US20190002577A1 (en) | 2016-01-04 | 2019-01-03 | Remd Biotherapeutics, Inc. | Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies |
| US20190248888A1 (en) | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| JP7005638B2 (en) | 2017-01-27 | 2022-02-04 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | Glucagon receptor-binding protein and how to use it |
| EP3829636A1 (en) | 2018-07-27 | 2021-06-09 | NGM Biopharmaceuticals, Inc. | Use of glucagon receptor antagonists with immunotherapeutic agent |
-
2018
- 2018-01-26 JP JP2019540056A patent/JP7005638B2/en active Active
- 2018-01-26 EP EP18744508.5A patent/EP3573651A4/en active Pending
- 2018-01-26 AU AU2018213374A patent/AU2018213374B2/en active Active
- 2018-01-26 PE PE2019001477A patent/PE20191404A1/en unknown
- 2018-01-26 MX MX2019008722A patent/MX2019008722A/en unknown
- 2018-01-26 UA UAA201908559A patent/UA129078C2/en unknown
- 2018-01-26 MY MYPI2019003796A patent/MY201301A/en unknown
- 2018-01-26 SG SG11201906682YA patent/SG11201906682YA/en unknown
- 2018-01-26 BR BR112019015479-5A patent/BR112019015479A2/en unknown
- 2018-01-26 US US15/881,493 patent/US10995145B2/en active Active
- 2018-01-26 CN CN201880011175.9A patent/CN110520151B/en active Active
- 2018-01-26 IL IL267638A patent/IL267638B2/en unknown
- 2018-01-26 CA CA3048913A patent/CA3048913A1/en active Pending
- 2018-01-26 WO PCT/US2018/015452 patent/WO2018140729A1/en not_active Ceased
- 2018-01-26 KR KR1020197023223A patent/KR102627311B1/en active Active
-
2019
- 2019-07-09 PH PH12019501605A patent/PH12019501605A1/en unknown
- 2019-07-25 CL CL2019002081A patent/CL2019002081A1/en unknown
- 2019-08-21 CO CONC2019/0009035A patent/CO2019009035A2/en unknown
-
2021
- 2021-03-19 US US17/206,910 patent/US11732049B2/en active Active
-
2023
- 2023-06-27 US US18/342,572 patent/US20240084023A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN110520151B (en) | 2024-04-12 |
| PH12019501605A1 (en) | 2020-06-01 |
| KR20190113815A (en) | 2019-10-08 |
| US20210332144A1 (en) | 2021-10-28 |
| CO2019009035A2 (en) | 2020-01-17 |
| IL267638A (en) | 2019-08-29 |
| KR102627311B1 (en) | 2024-01-22 |
| WO2018140729A1 (en) | 2018-08-02 |
| NZ754886A (en) | 2024-04-26 |
| JP7005638B2 (en) | 2022-02-04 |
| EP3573651A4 (en) | 2020-10-14 |
| US20180273629A1 (en) | 2018-09-27 |
| PE20191404A1 (en) | 2019-10-04 |
| UA129078C2 (en) | 2025-01-08 |
| EP3573651A1 (en) | 2019-12-04 |
| AU2018213374A1 (en) | 2019-07-11 |
| RU2019126781A (en) | 2021-03-01 |
| AU2018213374B2 (en) | 2024-09-05 |
| IL267638B1 (en) | 2025-04-01 |
| US10995145B2 (en) | 2021-05-04 |
| US11732049B2 (en) | 2023-08-22 |
| CN110520151A (en) | 2019-11-29 |
| MX2019008722A (en) | 2019-10-02 |
| BR112019015479A2 (en) | 2020-03-31 |
| US20240084023A1 (en) | 2024-03-14 |
| JP2020506692A (en) | 2020-03-05 |
| CL2019002081A1 (en) | 2019-12-20 |
| CA3048913A1 (en) | 2018-08-02 |
| MY201301A (en) | 2024-02-15 |
| RU2019126781A3 (en) | 2021-10-27 |
| IL267638B2 (en) | 2025-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201906682YA (en) | Glucagon receptor binding proteins and methods of use thereof | |
| SG11201907427YA (en) | Engineered transferrin receptor binding polypeptides | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
| SG11201907580SA (en) | Combination therapies for treatment of bcma-related cancers and autoimmune disorders | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201908238SA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201803676PA (en) | Site specific her2 antibody drug conjugates | |
| SG11201909561RA (en) | Octree-based convolutional neural network | |
| SG11201908092RA (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| SG11201810801QA (en) | Brain delivery protein |